Clinical trialNCT06028074RecruitingPhase 1/PHASE2Interventional

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

SponsorGeorgiamune IncEnrollment111Advanced Solid Malignancies

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Omid Hamid, MD
The Angeles Clinic and Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

the Angeles Clinic and Research Institute
Los Angeles, California, United States
Omid Hamid, MD, PhD
Recruiting
Ucla Hematology/oncology
Los Angeles, California, United States
Bartosz Chmielowski, MD, PhD
Recruiting
Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
Gino In, MD
Recruiting
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Katy Tsai, MD
Recruiting
Florida Cancer Specialists
Sarasota, Florida, United States
Manish Rajni Patel, MD
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Jaspreet Grewal, MD, PhD
Recruiting
Rutgers Cancer Institute of Nj
New Brunswick, New Jersey, United States
Sanjay Goel, MD
Recruiting
Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Jeffery S Russell, MD, PhD
Recruiting
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas, United States
Thomas Hutson, DO
Recruiting
Next Oncology Dallas
Irving, Texas, United States
Shiraj Sen, MD, PhD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Jonathan Berkman, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GIM122

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Dec 2023
Primary completion: 30 Sept 2026
Completion: 31 Dec 2026
Last update posted: 17 Aug 2026
Registered enrollment: 111
Registry id: NCT06028074

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.